System-Specific Biopharmaceuticals

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

The Global Luminex Multiplex Assays Market is projected to grow from USD 1.82 billion in 2025 to USD 3.89 billion by 2033, at a CAGR of 10.0%. This growth is driven by the rising demand for high-throughput biomarker profiling and standardized testing workflows. Key factors include the efficiency of multiplex systems, regulatory support for standardized panels, and the expansion of outsourced research models. However, challenges such as validation complexity and elevated costs may impact adoption rates.

fidelity

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

ATNF

ATNFW

RSLS

SBIO

Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio | NMLSF Stock News

StockTitan

180 Life Sciences

ReShape Lifesciences

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Global X HealthTech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio | NMLSF Stock News

Restart Life Sciences Corp. has announced a collaboration with the University of Manitoba's Richardson Centre for Food Technology and Research to support food-related scientific studies. This partnership aims to enhance product development for its functional wellness portfolio, including BrainQ™, BrainBalls™, and Holy Crap™ brands. The collaboration will focus on validating formulations, optimizing ingredients, and ensuring product quality. Additionally, the company clarified details regarding a previously announced loan financing of CAD$250,000, which includes interest and share purchase warrants.

Restart Life Announces Collaboration with University of Manitoba's Centre for Food Technology and Research | NMLSF Stock News

Restart Life Sciences has acquired Holy Crap Foods Inc., gaining 100% ownership of the functional cereal brand and its assets, which adds over $1 million in annual revenue. This acquisition allows Restart Life to become a revenue-producing organization and control a manufacturing facility in Gibsons, B.C. The company plans to leverage Holy Crap’s established customer base for expansion in the health and wellness sector. The latest analyst rating for Stuhini Exploration (TSE:NOVA) is a Hold with a price target of C$0.21, reflecting concerns over financial performance despite some positive technical indicators.

Tip Ranks

SPDR S&P Health Equip

Biolife4d Corp

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Restart Life Sciences Becomes Revenue Producer With Holy Crap Foods Acquisition

LIR Life Sciences Corp. announced positive interim results from a comparative mouse study on a CPP-enabled, needle-free delivery of GLP/GIP-based therapies. The study showed that animals treated with a novel semaglutide/CPP topical formulation had reduced blood glucose levels compared to untreated controls. This indicates that the CPP-enabled topical formulation can effectively deliver active drugs across the skin barrier, achieving sustained glucose control. The findings support further development of the transdermal platform for obesity treatments, aiming to provide alternatives to injectable drugs.

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies | BBCMF Stock News

ETHZW

Earnings Watch

ETHZILLA CORPORATION C/WTS 06/11/2025(TO PUR COM)

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.3

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.67

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM)(ATNFW.US)

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio | NMLSF Stock News

Restart Life Announces Collaboration with University of Manitoba's Centre for Food Technology and Research | NMLSF Stock News

Restart Life Sciences Becomes Revenue Producer With Holy Crap Foods Acquisition

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies | BBCMF Stock News

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.3

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.67